Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes
- 1 February 2005
- journal article
- research article
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 329 (2) , 62-65
- https://doi.org/10.1097/00000441-200502000-00002
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradoxACC Current Journal Review, 2004
- Lipid-Lowering Therapy With Statins in High-Risk Elderly PatientsJAMA, 2004
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Safety considerations for statinsCurrent Opinion in Lipidology, 2002
- Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic DrugsSeminars in Liver Disease, 2002
- Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial InfarctionCirculation, 2001
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- The Regenstrief Medical Record System: a quarter century experienceInternational Journal of Medical Informatics, 1999
- Ator vastatin-induced acute hepatitis with absence of cross-toxicity with simvastatinThe Lancet, 1999
- Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatinDigestive Diseases and Sciences, 1994